Mesothelin expression and survival outcomes in triple receptor negative breast cancer

Clinical Breast Cancer

Volumn 13, Issue 5, 2013, Pages 378-384

  Parinyanitikul, Napa ^a   Blumenschein, George R ^a   Wu, Yun ^a   Lei, Xiudong ^a   Chavez Macgregor, Mariana ^a   Smart, Melody ^a   Gonzalez Angulo, Ana Maria ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Mesothelin expression; Prognosis; Triple negative breast cancer

Indexed keywords

MESOTHELIN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER;

MESOTHELIN EXPRESSION; PROGNOSIS; TRIPLE-NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GPI-LINKED PROTEINS; HUMANS; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883762546     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.05.001     Document Type: Article

References (32)

1. K. Chang, and I. Pastan Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers Proc Natl Acad Sci USA 93 1996 136 140
2. T.K. Bera, and I. Pastan Mesothelin is not required for normal mouse development or reproduction Mol Cell Biol 20 2000 2902 2906
3. A. Rump, Y. Morikawa, and M. Tanaka Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion J Biol Chem 279 2004 9190 9198
4. K. Chang, I. Pastan, and M.C. Willingham Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium Int J Cancer 50 1992 373 381
5. K. Chang, L.H. Pai, and H. Pass Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma Am J Surg Pathol 16 1992 259 268
6. P. Argani, C. Iacobuzio-Donahue, and B. Ryu Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 7 2001 3862 3868
7. S.L. Swierczynski, A. Maitra, and S.C. Abraham Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays Hum Pathol 35 2004 357 366
8. R. Hassan, Z.G. Laszik, and M. Lerner Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis Am J Clin Pathol 124 2005 838 845
9. R. Hassan, and M. Ho Mesothelin targeted cancer immunotherapy Eur J Cancer 44 2008 46 53
10. W.F. Cheng, C.Y. Huang, and M.C. Chang High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma Br J Cancer 100 2009 1144 1153
11. T. Einama, H. Kamachi, and H. Nishihara Co-expression of mesothelin and CA125 correlates with unfavourable patient outcome in pancreatic ductal adenocarcinoma Pancreas 40 2011 1276 1282
12. K. Baba, S. Ishigami, and T. Arigami Mesothelin expression correlates with prolonged patient survival in gastric cancer J Surg Oncol 105 2012 195 199
13. M.J. Yen, C.Y. Hsu, and T.L. Mao Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma Clin Cancer Res 12 2006 827 831
14. T. Einama, S. Homma, and H. Kamachi Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer Br J Cancer 107 2012 137 142
15. O.D. Roe, J. Creaney, and S. Lundgren Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study Lung Cancer 61 2008 235 243
16. L. Wang, Z. Niu, and L. Zhang Clinicopathological significance of mesothelin expression in invasive breast cancer J Int Med Res 40 2012 909 916
17. E.A. Rakha, T.C. Putti, and D.M. Abd El-Rehim Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation J Pathol 208 2006 495 506
18. P.L. Nguyen, A.G. Taghian, and M.S. Katz Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy J Clin Oncol 26 2008 2373 2378
19. E.A. Rakha, J.S. Reis-Filho, and I.O. Ellis Basal-like breast cancer: a critical review J Clin Oncol 26 2008 2568 2581
20. H. Kennecke, R. Yerushalmi, and R. Woods Metastatic behavior of breast cancer subtypes J Clin Oncol 28 2010 3271 3277
21. J. Tchou, L.C. Wang, and B. Selven Mesothelin, a novel immunotherapy target for triple negative breast cancer Breast Cancer Res Treat 133 2012 799 804
22. J. Tabernero, F. Rojo, and E. Calvo Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Clin Oncol 26 2008 1603 1610
23. K.S. McCarty Jr., L.S. Miller, and E.B. Cox Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies Arch Pathol Lab Med 109 1985 716 721
24. S. Shousha, and D. Peston Immunohistochemical demonstration of oestrogen and progesterone receptors in paraffin sections of breast carcinoma Curr Diag Pathol 4 1997 176 180
25. N.G. Ordonez Value of mesothelin immunostaining in the diagnosis of mesothelioma Mod Pathol 16 2003 192 197
26. M.E. Hammond, D.F. Hayes, and M. Dowsett American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2010 2784 2795
27. K.P. Raghav, L.F. Hernandez-Aya, and X. Lei Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers Cancer 118 2012 1498 1506
28. R. Hassan, T. Bera, and I. Pastan Mesothelin: a new target for immunotherapy Clin Cancer Res 10 2004 3937 3942
29. R. Hassan, S.J. Cohen, and M. Phillips Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers Clin Cancer Res 16 2010 6132 6138
30. R.J. Kelly, E. Sharon, and I. Pastan Mesothelin-targeted agents in clinical trials and in preclinical development Mol Cancer Ther 11 2012 517 525
31. J. Ma, W.K. Tang, and L. Esser Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights J Biol Chem 287 2012 33123 33131
32. K. Wang, V. Bodempudi, and Z. Liu Inhibition of mesothelin as a novel strategy for targeting cancer cells PLoS One 7 2012 e33214